Literature DB >> 24900696

Selective Inhibitors of Fibroblast Activation Protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold.

Koen Jansen1, Leen Heirbaut1, Jonathan D Cheng2, Jurgen Joossens1, Oxana Ryabtsova1, Paul Cos3, Louis Maes3, Anne-Marie Lambeir4, Ingrid De Meester4, Koen Augustyns1, Pieter Van der Veken1.   

Abstract

Fibroblast activation protein (FAP) is a serine protease that is generally accepted to play an important role in tumor growth and other diseases involving tissue remodeling. Currently there are no FAP inhibitors with reported selectivity toward both the closely related dipeptidyl peptidases (DPPs) and prolyl oligopeptidase (PREP). We present the discovery of a new class of FAP inhibitors with a N-(4-quinolinoyl)-Gly-(2-cyanopyrrolidine) scaffold. We have explored the effects of substituting the quinoline ring and varying the position of its sp(2) hybridized nitrogen atom. The most promising inhibitors combined low nanomolar FAP inhibition and high selectivity indices (>10(3)) with respect to both the DPPs and PREP. Preliminary experiments on a representative inhibitor demonstrate that plasma stability, kinetic solubility, and log D of this class of compounds can be expected to be satisfactory.

Entities:  

Keywords:  Fibroblast activation protein (FAP); dipeptidyl peptidase IV (DPPIV); prolyl oligopeptidase (PREP); seprase

Year:  2013        PMID: 24900696      PMCID: PMC4027141          DOI: 10.1021/ml300410d

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  27 in total

Review 1.  Emerging roles of serine proteinases in tissue turnover in arthritis.

Authors:  J M Milner; A Patel; A D Rowan
Journal:  Arthritis Rheum       Date:  2008-12

2.  Synthesis and structure-activity relationship of N-acyl-Gly-, N-acyl-Sar- and N-blocked-boroPro inhibitors of FAP, DPP4, and POP.

Authors:  Thuy Tran; Clifford Quan; Conrad Yap Edosada; Mark Mayeda; Christian Wiesmann; Dan Sutherlin; Beni B Wolf
Journal:  Bioorg Med Chem Lett       Date:  2006-12-01       Impact factor: 2.823

3.  Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth.

Authors:  Jonathan D Cheng; Matthildi Valianou; Adrian A Canutescu; Eileen K Jaffe; Hyung-Ok Lee; Hao Wang; Jack H Lai; William W Bachovchin; Louis M Weiner
Journal:  Mol Cancer Ther       Date:  2005-03       Impact factor: 6.261

4.  Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein alpha.

Authors:  Kathleen Aertgeerts; Irena Levin; Lihong Shi; Gyorgy P Snell; Andy Jennings; G Sridhar Prasad; Yanming Zhang; Michelle L Kraus; Shant Salakian; Vandana Sridhar; Robert Wijnands; Mike G Tennant
Journal:  J Biol Chem       Date:  2005-04-04       Impact factor: 5.157

Review 5.  Prolyl peptidases related to dipeptidyl peptidase IV: potential of specific inhibitors in drug discovery.

Authors:  Pieter Van der Veken; Achiel Haemers; Koen Augustyns
Journal:  Curr Top Med Chem       Date:  2007       Impact factor: 3.295

6.  Substituted 4-carboxymethylpyroglutamic acid diamides as potent and selective inhibitors of fibroblast activation protein.

Authors:  Ting-Yueh Tsai; Teng-Kuang Yeh; Xin Chen; Tsu Hsu; Yu-Chen Jao; Chih-Hsiang Huang; Jen-Shin Song; Yu-Chen Huang; Chia-Hui Chien; Jing-Huai Chiu; Shih-Chieh Yen; Hung-Kuan Tang; Yu-Sheng Chao; Weir-Torn Jiaang
Journal:  J Med Chem       Date:  2010-09-23       Impact factor: 7.446

7.  Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice.

Authors:  Angélica M Santos; Jason Jung; Nazneen Aziz; Joseph L Kissil; Ellen Puré
Journal:  J Clin Invest       Date:  2009-11-16       Impact factor: 14.808

Review 8.  On the edge of validation--cancer protease fibroblast activation protein.

Authors:  Beni B Wolf; Clifford Quan; Thuy Tran; Christian Wiesmann; Daniel Sutherlin
Journal:  Mini Rev Med Chem       Date:  2008-06       Impact factor: 3.862

Review 9.  Seprase: an overview of an important matrix serine protease.

Authors:  Pamela O'Brien; Brendan F O'Connor
Journal:  Biochim Biophys Acta       Date:  2008-01-26

10.  Fibroblast activation protein is expressed by rheumatoid myofibroblast-like synoviocytes.

Authors:  Stefan Bauer; Michael C Jendro; Andreas Wadle; Sascha Kleber; Frank Stenner; Robert Dinser; Anja Reich; Erica Faccin; Stefan Gödde; Harald Dinges; Ulf Müller-Ladner; Christoph Renner
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

View more
  32 in total

1.  Design and Development of 99mTc-Labeled FAPI Tracers for SPECT Imaging and 188Re Therapy.

Authors:  Thomas Lindner; Annette Altmann; Susanne Krämer; Christian Kleist; Anastasia Loktev; Clemens Kratochwil; Frederik Giesel; Walter Mier; Frederik Marme; Jürgen Debus; Uwe Haberkorn
Journal:  J Nucl Med       Date:  2020-03-13       Impact factor: 10.057

2.  Molecular Imaging of Fibroblast Activity After Myocardial Infarction Using a 68Ga-Labeled Fibroblast Activation Protein Inhibitor, FAPI-04.

Authors:  Zohreh Varasteh; Sarajo Mohanta; Stephanie Robu; Miriam Braeuer; Yuanfang Li; Negar Omidvari; Geoffrey Topping; Ting Sun; Stephan G Nekolla; Antonia Richter; Christian Weber; Andreas Habenicht; Uwe A Haberkorn; Wolfgang A Weber
Journal:  J Nucl Med       Date:  2019-08-12       Impact factor: 10.057

3.  Novel Small Molecule-Derived, Highly Selective Substrates for Fibroblast Activation Protein (FAP).

Authors:  An De Decker; Gwendolyn Vliegen; Dries Van Rompaey; Anke Peeraer; An Bracke; Line Verckist; Koen Jansen; Ruth Geiss-Friedlander; Koen Augustyns; Hans De Winter; Ingrid De Meester; Anne-Marie Lambeir; Pieter Van der Veken
Journal:  ACS Med Chem Lett       Date:  2019-07-09       Impact factor: 4.345

4.  Distinguishing Benign and Malignant Findings on [68 Ga]-FAPI PET/CT Based on Quantitative SUV Measurements.

Authors:  M Dabir; E Novruzov; K Mattes-György; M Beu; K Dendl; C Antke; S A Koerber; M Röhrich; C Kratochwil; J Debus; U Haberkorn; F L Giesel
Journal:  Mol Imaging Biol       Date:  2022-08-23       Impact factor: 3.484

5.  Tumor-targeting efficacy of a BF211 prodrug through hydrolysis by fibroblast activation protein-α.

Authors:  Xiao-Ping Chai; Guang-Long Sun; Yan-Fen Fang; Li-Hong Hu; Xuan Liu; Xiong-Wen Zhang
Journal:  Acta Pharmacol Sin       Date:  2017-11-09       Impact factor: 6.150

Review 6.  Bismuth-213 for Targeted Radionuclide Therapy: From Atom to Bedside.

Authors:  Stephen Ahenkorah; Irwin Cassells; Christophe M Deroose; Thomas Cardinaels; Andrew R Burgoyne; Guy Bormans; Maarten Ooms; Frederik Cleeren
Journal:  Pharmaceutics       Date:  2021-04-21       Impact factor: 6.321

7.  Imaging of Fibroblast Activation Protein in Cancer Xenografts Using Novel (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine-Based Small Molecules.

Authors:  Stephanie L Slania; Deepankar Das; Ala Lisok; Yong Du; Zirui Jiang; Ronnie C Mease; Steven P Rowe; Sridhar Nimmagadda; Xing Yang; Martin G Pomper
Journal:  J Med Chem       Date:  2021-03-17       Impact factor: 8.039

8.  A Trifunctional Theranostic Ligand Targeting Fibroblast Activation Protein-α (FAPα).

Authors:  James M Kelly; Thomas M Jeitner; Shashikanth Ponnala; Clarence Williams; Anastasia Nikolopoulou; Stephen G DiMagno; John W Babich
Journal:  Mol Imaging Biol       Date:  2021-03-15       Impact factor: 3.488

Review 9.  The Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including Atherosclerosis.

Authors:  Yannick Waumans; Lesley Baerts; Kaat Kehoe; Anne-Marie Lambeir; Ingrid De Meester
Journal:  Front Immunol       Date:  2015-08-07       Impact factor: 7.561

Review 10.  Current Landscape of Breast Cancer Imaging and Potential Quantitative Imaging Markers of Response in ER-Positive Breast Cancers Treated with Neoadjuvant Therapy.

Authors:  Ella F Jones; Deep K Hathi; Rita Freimanis; Rita A Mukhtar; A Jo Chien; Laura J Esserman; Laura J Van't Veer; Bonnie N Joe; Nola M Hylton
Journal:  Cancers (Basel)       Date:  2020-06-09       Impact factor: 6.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.